Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM407I6)

Drug Name
BAY 853934 Drug Info
Synonyms
Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H
Indication
Disease Entry ICD 11 Status REF
Anaemia 3A90 Phase 3 [1]
Cross-matching ID
PubChem CID
59603622
CAS Number
CAS 1154028-82-6
TTD Drug ID
DM407I6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting HIF-prolyl hydroxylase (HPH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclopirox DMN5T2A Cutaneous candidiasis 1F23.14 Approved [3]
AKB-6548 DM2EJM3 Anaemia 3A90 Phase 3 [4]
JTZ-951 DM8FSPV Anaemia 3A90 Phase 3 [5]
FG-2216 DM7RYL4 Kidney disease GC2Z Phase 2 [6]
DS-1093 DM42KZW Anemia 3A00-3A9Z Phase 1 [7]
ZYAN1 DM796RI Anaemia 3A90 Phase 1 [8]
JNJ-42905343 DMCNBHY Anaemia 3A90 Preclinical [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03418168) A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD). U.S. National Institutes of Health.
2 Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 DOI: 10.1038/nrd4422
5 DOI: 10.1038/nrneph.2015.82
6 Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
7 Company report (Daiichisankyo)
8 Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
9 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.